血管性癡呆是指由于各種腦血管疾病所導(dǎo)致的獲得性智能障礙綜合癥.隨著人口的老齡化、飲食結(jié)構(gòu)的改變,血管性癡呆的發(fā)病率呈逐年增加的趨勢.奧拉西坦是一種代表性的具有吡咯烷酮結(jié)構(gòu)的促智藥,臨床上用于治療健忘癥、老年性癡呆、血管性癡呆等.近年來有關(guān)奧拉西坦單獨(dú)或聯(lián)合用藥治療血管性癡呆的研究越來越多,特別是聯(lián)合用藥,通過不同藥物的協(xié)同作用顯著提高血管性癡呆的治療效果.對奧拉西坦及其聯(lián)合用藥治療血管性癡呆臨床應(yīng)用的研究進(jìn)展進(jìn)行綜述,為血管性癡呆的臨床用藥提供參考.

Vascular dementia (VD) is a kind of cognitive dysfunction caused by a number of cardiovascular diseases. With the aging of the population and changes in diet, VD incidence showed a rising trend. Oxiracetam is a representative nootropic drug with the structure of pyrrolidone used for the treatment of amnesia, Alzheimer's disease, vascular dementia, etc. In recent years, there are more and more studies on single or combination therapy with oxiracetam, especially the combination therapy, the results indicate that the combination of drugs through different mechanisms and synergy can significantly improve the therapeutic effect of VD. The research progress on the single or combined use of oxiracetam is introduced in this article. It could provide a reference for clinical treatment of vascular dementia.

遼寧省教育廳科學(xué)研究一般項(xiàng)目(L2012146)